Enterprise Value
-5.683M
Cash
18.36M
Avg Qtr Burn
-17.14M
Short % of Float
20.44%
Insider Ownership
47.53%
Institutional Own.
30.53%
Qtr Updated
06/30/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Batiraxcept (AVB-500) Details Renal cell carcinoma | Phase 3 Initiation | |
Batiraxcept (AVB-500) Details Solid tumor/s, Cancer, Renal cell carcinoma | Phase 3 Initiation | |
Batiraxcept (AVB-500) Details Pancreatic cancer | Failed Discontinued | |
Batiraxcept (AVB-500) Details Ovarian cancer, Solid tumor/s, Cancer | Failed Discontinued |